Inflammation induced by tumor-associated nerves promotes resistance to anti-PD-1 therapy in cancer patients and is targetable by interleukin-6 blockade
Erez N Baruch,Priyadahrshini Nagarajan,Frederico O Gleber-Netto,Xiayu Rao,Tongxin Xie,Shamima Akhter,Adebayo Adewale,Islam Shajedul,Brandi J Mattson,Renata Ferrarotto,Michael K Wong,Michael A Davies,Sonali Jindal,Sreyashi Basu,Catherine Harwood,Irene Leigh,Nadim Ajami,Andrew Futreal,Micah Castillo,Preethi Gunaratne,Ryan P Goepfert,Nikhil Khushalani,Jing Wang,Stephanie Watowich,George A Calin,Michael R Migden,Paola Vermeer,Nisha D'Silva,Dan Yaniv,Jared K Burks,Javier Gomez,Patrick M Dougherty,Kenneth Y Tsai,James P Allison,Padmanee Sharma,Jennifer Wargo,Jeffrey N Myers,Neil D Gross,Moran Amit
DOI: https://doi.org/10.21203/rs.3.rs-3161761/v1
2023-07-18
Abstract:While the nervous system has reciprocal interactions with both cancer and the immune system, little is known about the potential role of tumor associated nerves (TANs) in modulating anti-tumoral immunity. Moreover, while peri-neural invasion is a well establish poor prognostic factor across cancer types, the mechanisms driving this clinical effect remain unknown. Here, we provide clinical and mechniastic association between TANs damage and resistance to anti-PD-1 therapy. Using electron microscopy, electrical conduction studies, and tumor samples of cutaneous squamous cell carcinoma (cSCC) patients, we showed that cancer cells can destroy myelin sheath and induce TANs degeneration. Multi-omics and spatial analyses of tumor samples from cSCC patients who underwent neoadjuvant anti-PD-1 therapy demonstrated that anti-PD-1 non-responders had higher rates of peri-neural invasion, TANs damage and degeneration compared to responders, both at baseline and following neoadjuvant treatment. Tumors from non-responders were also characterized by a sustained signaling of interferon type I (IFN-I) - known to both propagate nerve degeneration and to dampen anti-tumoral immunity. Peri-neural niches of non-responders were characterized by higher immune activity compared to responders, including immune-suppressive activity of M2 macrophages, and T regulatory cells. This tumor promoting inflammation expanded to the rest of the tumor microenvironment in non-responders. Anti-PD-1 efficacy was dampened by inducing nerve damage prior to treatment administration in a murine model. In contrast, anti-PD-1 efficacy was enhanced by denervation and by interleukin-6 blockade. These findings suggested a potential novel anti-PD-1 resistance drived by TANs damage and inflammation. This resistance mechanism is targetable and may have therapeutic implications in other neurotropic cancers with poor response to anti-PD-1 therapy such as pancreatic, prostate, and breast cancers.